Leerink on Fulcrum Therapeutics (FULC): 'We believe this is a positive sign for FULC'
March 31, 2026 1:08 PM
Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating and $47.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
